{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:19Z","timestamp":1787505919158,"version":"build-2736575974"},"reference-count":10,"publisher":"Centers for Disease Control MMWR Office","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6725a5","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T11:28:47Z","timestamp":1530185327000},"page":"723-726","source":"Crossref","is-referenced-by-count":93,"title":["Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent\n                    <i>Mycobacterium tuberculosis<\/i>\n                    Infection"],"prefix":"10.15585","volume":"67","author":[{"given":"Andrey S.","family":"Borisov","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Bamrah Morris","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibril J.","family":"Njie","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla A.","family":"Winston","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deron","family":"Burton","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yelk Woodruff","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeanna","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"LoBue","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R1","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.","volume":"60","author":"CDC","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0749-3797(99)00119-1","article-title":"Developing an evidence-based Guide to Community Preventive Services\u2014methods.","volume":"18","author":"Briss","year":"2000","journal-title":"Am J Prev Med"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0749-3797(99)00122-1","article-title":"Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services.","volume":"18","author":"Zaza","year":"2000","journal-title":"Am J Prev Med"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis.","author":"Njie","year":"2018","journal-title":"Am J Prev Med"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention.","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial.","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.mm6725a5-201806281128-R10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis study.","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T23:35:58Z","timestamp":1571528158000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6725a5.htm?s_cid=mm6725a5_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":10,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2018,6,29]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6725a5","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,29]]},"published":{"date-parts":[[2018,6,29]]}}}